

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/441,140
(use as many sheets as necessary)		Filing Date	November 16, 1999
Sheet	1	of	1
		Examiner Name	C. Nichols
		Attorney Docket Number	SOLOMON=1R

Examiner Initials*	Cite No. ¹	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)	MM-DD-YYYY		
CSJ	FU	US 00/201,430	11/30/1998	Schenk	
		US 09/497,553	02/03/2000	Schenk	
		US 09/724,177	11/28/2000	Schenk	
		US 00/702,027	11/28/2000	Schenk	
		US 00/724,762	11/28/2000	Schenk	
		US 09/724,493	11/28/2000	Schenk	
		US 09/724,480	11/28/2000	Schenk	
	FV	US 09/592,399	05/28/1999	Schenk	
		US 09/723,713	11/27/2000	Schenk	
		US 09/723,768	11/27/2000	Schenk	
		US 00/724,210	11/27/2000	Schenk	
		US 09/720,304	11/27/2000	Schenk	
		US 09/724,485	11/27/2000	Schenk	
	PW	US 09/580,845	05/26/2000	Schenk	
		US 09/724,610	11/28/2000	Schenk	
		US 09/724,061	11/28/2000	Schenk	
	FX	US 00/680,018	05/26/2000	Schenk et al.	
		US 09/724,552	11/28/2000	Schenk et al.	
		US 09/592,544	11/28/2000	Schenk et al.	
		US 00/724,273	11/28/2000	Schenk et al.	
		US 09/724,551	11/28/2000	Schenk et al.	
		US 09/724,285	11/28/2000	Schenk et al.	
	FT	US 09/300,010	05/28/00	Schenk et al.	
		US 09/720,760	11/28/2000	Schenk et al.	
		US 09/724,291	11/28/2000	Schenk et al.	
		US 09/070,701	05/13/2001	Schenk	

~~CONFIDENTIAL; DO NOT PRINT~~

Examiner Signature	L. Mirel	Date Considered	5/6/04
-----------------------	----------	--------------------	--------

*** EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **¹** Applicant's unique citation designation number (optional). **²** See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. **³** Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). **⁴** For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **⁵** Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. **⁶** Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
				Application Number	09/441,140
				Filing Date	November 16, 1999
				First Named Inventor	Beka SOLOMON
				Group Art Unit	4642 (K47)
				Examiner Name	G. Bansal NICHOLS
Sheet	1	of	2	Attorney Docket Number	SOLOMON=1R

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
CGD	AE	5,750,349	A	Suzuki et al	05-12-1998
	AF	5,753,624	A	McMichael et al	05-19-1998
↓	AG	5,851,996	A	Kline	12-22-1998
CGD	AH	5,955,317	A	Suzuki et al	09-21-1999


FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office ³	Number		
CGD	AI	WO	95/31996	A1 MILKHAUS LABORATORY	11-30-1995

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
CGD	AJ	DELIMASTRO et al, "Immunogenicity of filamentous phage displaying peptide mimotopes after oral administration", <u>Vaccine</u> 15(11):1276-1285 (1997)
	AK	DODART et al, "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model", <u>Nat Neurosci</u> 5(5):452-457 (2002) (published online April 8, 2002, pp. 1-6)
	AL	JANUS et al, "A β peptide immunization reduces behavioral impairment and plaques in a model of Alzheimer's disease", <u>Nature</u> 408(6815):979-982 (2000)
	AM	MANOUTCHARIAN et al, "Phage Displayed Biomolecules As Preventive and Therapeutic Agents", <u>Curr Pharm Biotechnol</u> 2(3):217-223 (2001)
	AN	MORGAN et al, "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease" <u>Nature</u> 408(6815):982-985 (2000)
	AO	SEUBERT et al, "Isolation and quantification of soluble Alzheimer's β -peptide from biological fluids", <u>Nature</u> 359(6393):325-327 (1992)
↓	AP	Elan Internet Press Release, "Elan and AHP provide an update on the phase 2A Clinical Trial of AN-1792", January 18, 2002 (www.elan.com/NewsRoom)
CGD	AQ	Elan Internet Press Release, "Elan and Wyeth provide update on status of Alzheimer's collaboration", March 2002 (www.elan.com/NewsRoom)

Examiner Signature	<i>Gene S</i>	Date Considered	7/30/02	RECEIVED
			1600/2900	AUG 28 2002

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 1647
Examiner Name	S.Unger DICHTULS

Attorney Docket Number

SOLOMON=1R

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document Number	Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ESD	AR	6,417,178	B1	Klunk et al	07-09-2002	RECEIVED TECH CENTER 2000 10002000
	AS	6,284,221	B1	Schenk et al	09-04-2001	RECEIVED TECH CENTER 2000 10002000
	AT	6,262,335	B1	Hsiao et al	07-17-2001	RECEIVED TECH CENTER 2000 10002000
	AU	6,114,133	—	Seubert et al	09-05-2000	RECEIVED TECH CENTER 2000 10002000
	AV	5,958,883	—	Snow	09-28-1999	RECEIVED TECH CENTER 2000 10002000
	AW	5,955,079	—	Mond et al	09-21-1999	RECEIVED TECH CENTER 2000 10002000
	AX	5,877,399	—	Hsiao et al	03-02-1999	RECEIVED TECH CENTER 2000 10002000
	AY	5,869,093	—	Weiner et al	02-09-1999	RECEIVED TECH CENTER 2000 10002000
	AZ	5,869,054	—	Weiner et al	02-09-1999	RECEIVED TECH CENTER 2000 10002000
	BA	5,849,298	—	Weiner et al	12-15-1998	RECEIVED TECH CENTER 2000 10002000
	BB	5,837,473	—	Maggio et al	11-17-1998	RECEIVED TECH CENTER 2000 10002000
	BC	5,780,587	—	Potter	07-14-1998	RECEIVED TECH CENTER 2000 10002000
	BD	5,744,368	—	Goldgaber et al	04-28-1998	RECEIVED TECH CENTER 2000 10002000
	BE	5,738,142	—	Sette et al	04-07-1998	RECEIVED TECH CENTER 2000 10002000
	BF	5,733,547	—	Weiner et al	03-31-1998	RECEIVED TECH CENTER 2000 10002000
	BG	5,679,348	—	Nesburn et al	10-21-1997	RECEIVED TECH CENTER 2000 10002000
	BH	5,645,820	—	Hafler et al	07-08-1997	RECEIVED TECH CENTER 2000 10002000
	BI	5,641,474	—	Hafler et al	06-24-1997	RECEIVED TECH CENTER 2000 10002000
	BJ	5,641,473	—	Hafler et al	06-24-1997	RECEIVED TECH CENTER 2000 10002000
	BK	5,612,486	—	McConlogue et al	03-18-1997	RECEIVED TECH CENTER 2000 10002000
	BL	5,605,811	—	Seubert et al	02-25-1997	RECEIVED TECH CENTER 2000 10002000
	BM	5,585,100	—	Mond et al	12-17-1997	RECEIVED TECH CENTER 2000 10002000
	BN	5,571,500	—	Hafler et al	11-05-1996	RECEIVED TECH CENTER 2000 10002000
	BO	5,571,499	—	Hafler et al	11-05-1996	RECEIVED TECH CENTER 2000 10002000
	BP	5,441,870	—	Seubert et al	08-15-1995	RECEIVED TECH CENTER 2000 10002000
	BQ	5,434,170	—	Andrusis, Jr.	07-18-1995	RECEIVED TECH CENTER 2000 10002000
	BR	5,387,742	—	Cordell	02-07-1995	RECEIVED TECH CENTER 2000 10002000
	BS	5,270,165	—	Van Nostrand et al	12-14-1993	RECEIVED TECH CENTER 2000 10002000
	BT	5,231,170	—	Averback	07-27-1993	RECEIVED TECH CENTER 2000 10002000
	BU	5,231,000	—	Majocha et al	07-27-1993	RECEIVED TECH CENTER 2000 10002000
	BV	5,220,013	—	Ponte et al	06-15-1993	RECEIVED TECH CENTER 2000 10002000
	BW	5,208,036	—	Eppstein et al	05-04-1993	RECEIVED TECH CENTER 2000 10002000
	BX	5,192,753	—	McGeer et al	03-09-1993	RECEIVED TECH CENTER 2000 10002000
	BY	5,187,153	—	Cordell et al	03-09-1993	RECEIVED TECH CENTER 2000 10002000
	BZ	5,057,540	—	Kensil et al	10-15-1991	RECEIVED TECH CENTER 2000 10002000
GN	CA	5,004,697	—	Pardridge	04-20-1991	RECEIVED TECH CENTER 2000 10002000
GN	CB	4,666,829	—	Glenner et al	05-19-1987	RECEIVED TECH CENTER 2000 10002000

Examiner Signature


G. M. Nichols

Date Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

She

1

1

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 - 1647
Examiner Name	Slinger - NICHOLS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Number		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number			
CC	WO	94/28412	A1	The Miriam Hospital	12-08-1994	██████████
CD	WO	94/03615	A1	Medeva Holdings B.V.	02-17-1994	██████████
CE	WO	94/01772	A1	Children's Med. Cen. Corp.	01-20-1994	██████████
CF	EP	0 276 723	B1	Bayer AG	12-08-1993	██████████
CG	WO	93/21950	A1	Medeva Holdings B.V.	11-11-1993	██████████
CH	WO	93/16724	A1	Autoimmune, Inc.	09-02-1993	██████████
CI	WO	93/15760	A1	Mond et al	08-19-1993	██████████
CJ	WO	93/14200	A1	TSI Corporation	07-22-1993	██████████
CK	WO	93/04194	A1	Regents of U. of Minn.	03-04-1993	██████████
CL	WO	93/02189	A1	Regents of U. of Cal.	02-04-1993	██████████
CM	WO	92/13069	A1	Imp. Col. of Sci, Tech. & Med.	08-06-1992	██████████
CN	WO	92/06708	A1	Brigham and Women's Hosp.	04-30-1992	██████████
CO	WO	92/06187	A1	The Upjohn Company	04-16-1992	██████████
CP	WO	91/19810	A1	California Biotechnology Inc.	12-26-1991	██████████
CQ	WO	91/16819	A1	Molecular Rx, Inc.	11-14-1991	██████████
CR	EP	0 451 700	A1	Miles Inc.	10-16-1991	██████████
CS	WO	91/12816	A1	Autoimmune, Inc.	09-05-1991	██████████
CT	WO	91/08760	A1	Brigham and Women's Hosp.	06-27-1991	██████████
CU	WO	90/12871	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990	██████████
CV	WO	90/12870	A1	Res. Found. Mental Hygiene, Inc.	11-01-1990	██████████
CW	GB	2 220 211	A	Ribi Immunochem Research Inc.	01-04-1990	██████████
CX	WO	89/06689	A1	McLean Hosp. Corp. & U. Roch.	07-27-1989	██████████
CY	WO	89/06242	A1	McLean Hosp. Corp. & U. Roch.	07-13-1989	██████████
CZ	WO	89/03687	A1	Genetics Institute, Inc.	05-05-1989	██████████
DA	WO	89/01343	A1	Regents of U. of Cal.	02-23-1989	██████████
DB	WO	88/10120	A1	Brigham and Women's Hosp.	12-29-1988	██████████

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>[Signature]</i>	DC	BARROW et al, "Solution Conformations and Aggregational Properties of Synthetic Amyloid β -Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra" <i>J Mol Biol</i> 225(4):1075-1093 (1992)	

**Examiner
Signature**

G. Nise

Date
Considered

113d03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

3

of

8

Complete if Known

TECH CENTER 1300-2100

NOV 13 2002

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 1647
Examiner Name	S. Ullgar NICHOLS

Attorney Docket Number

SOLOMON=1R

DD	BAUER et al, "Interleukin-6 and α -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Lett</u> 285(1):111-114 (1991)
DE	BICKEL et al, "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc for Neuroscience Abstracts</u> 18:764 (325.6) (1992)
DF	BODMER et al, "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem Biophys Res Commun</u> 171(2):890-897 (1990)
DG	BORIS-LAWRIE et al, "Recent advances in retrovirus vector technology," <u>Curr Opin Genet Dev</u> 3(1):102-109 (1993)
DH	BRICE et al, "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J Neurol Neurosurg Psychiatry</u> 56:112-113 (1993)
DI	CAPUTO et al, "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin Neuropharm</u> 15(S1):414A-415A (1992)
DJ	CHAO et al, "Transforming Growth Factor- β Protects Human Neurons Against β -Amyloid-Induced Injury," 23 rd Annual Meeting, Washington, DC, November 7-12, 1993, <u>Soc Neurosci Abstracts</u> 19:513.7 (1993)
DK	CHEN et al "An Antibody to β Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neurosci Lett</u> 125(2):223-226 (1991)
DL	CORDELL B " β -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>An. Rev Pharmacol Toxicol</u> 34:69-89 (1994)
DM	COSTA et al, "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand J Immunol</u> 38:177-182 (1993)
DN	ELIZAN et al, "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J Neurol Sci</u> 59(3):341-347 (1983)
DO	FELSENSTEIN et al, "Processing of the β -amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neurosci Lett</u> 152:185-189 (1993)
DP	FISHER et al, "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>Proc Natl Acad Sci</u> 88:1779-1782 (1991)
DQ	GANDY et al, "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> 13:108-113 (1992)

Examiner
SignatureDate
Considered

7/13/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

RECEIVED



TECH CENTER 1600
NOV 15 2002

RECEIVED

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 (607)
Examiner Name	S. Nagar J. NICHOLSON

Attorney Docket Number

SOLOMON=1R


DR	GARDELLA et al, "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem Biophys Res Comm</u> 173:1292-1298 (1990)
DS	GASKIN et al, "Human antibodies reactive with β -amyloid protein in Alzheimer's disease," <u>J Exp Med</u> 177:1181-1186 (1993)
DT	GLENNER et al, "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochem Biophys Res Comm</u> 120(3):885-890 (1984)
DU	GLENNER et al, "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochem Biophys Res Comm</u> 122(3): 1131-1135 (1984)
DV	GOATE et al, "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> 349:704-706 (1991)
DW	GORTNER, <u>Outlines of Biochemistry</u> , 3 rd Ed, Gorner et al Eds., John Wiley & Sons, Inc New York, pp. 322-323, (1949)
DX	HAASS et al "Amyloid β -peptide is produced by cultured cells during normal metabolism," <u>Nature</u> 359(6393):322-5 (1992)
DY	HAGA et al, "Synthetic Alzheimer amyloid β /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Res</u> 601:88-94 (1993)
DZ	HARRINGTON et al, "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of β /A4-protein," <u>Biochim Biophys Acta</u> 1158(2):120-128 (1993)
EA	HAZAMA et al, "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of <i>Escherichia Coli</i> Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> 78:643-649 (1993)
EB	HILBICH et al, "Human and rodent sequence analogs of Alzheimer's amyloid β A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur J Biochem</u> 201:61-69 (1991)
EC	HUBERMAN et al, "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J Neuroimmuno</u> 52(2):147-152 (1994)
ED	IKEDA et al, "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- β protein monoclonal antibody," <u>Lab Invest</u> 57(4):446-449 (1987)
EE	ITAGAKI et al, "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J Neuroimmunol</u> 24:173-182 (1989)

Examiner
SignatureDate
Considered

7/13/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1042-1647
Examiner Name	S. Linger JOACHIM
Attorney Docket Number	SOLOMON=1R

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
CG	EF	IWATSUBO et al, "Visualization of Aβ42(43) and Aβ40 in Senile Plaques with End-Specific Aβ Monoclonals: Evidence That an Initially Deposited Species Is Aβ42(43)," <u>Neuron</u> 13:45-53 (1994)
	EG	JANSEN et al, "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immunol Rev</u> 62:185-216 (1982)
	EH	JOACHIM et al, "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am J Pathol</u> 138(2):373-384 (1991)
	EI	KALARIA RN, "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res Immunol</u> 143:637-641 (1992)
	EJ	KAWABATA et al, "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> 354:476-478 (1991)
	EK	LAMPERT-ETCHELLS et al, "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993)
	EL	LANGER, "New Methods of Drug Delivery," <u>Science</u> 249:1527-1532 (1990)
	EM	LANNFELT et al, "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behav Brain Res</u> 57(2):207-213 (1993)
	EN	LOPEZ et al, "Serum auto-antibodies in Alzheimer's disease," <u>Acta Neurol Scand</u> 84(5):441-444 (1991)
	EO	MAJOCHA et al, "Development of a Monoclonal Antibody Specific for β/A4 Amyloid in Alzheimer's Disease Brain for Application to In Vivo Imaging of Amyloid Angiopathy," <u>J Nucl Med</u> 33:2184-2189 (1992)
CG	EP	MAK et al, "Polyclonals to β-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Res</u> 667:138-142 (1994)
CG	EQ	MASTERS et al, "Amyloid plaque core protein in Alzheimer disease and Down syndrome," <u>Proc Natl Acad Sci USA</u> 82:4245-4249 (1985)

Examiner Signature

Date Considered

7/30/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1642 (soft)
Examiner Name	S. Ungar PICTORSS
Attorney Docket Number	SOLOMON=1R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
CGO	ER	McGEER et al, "Immunohistochemical Localization of Beta-Amyloid Precursor Protein Sequences in Alzheimer and Normal Brain Tissue by Light and Electron Microscopy," <u>J Neurosci Res</u> 31:428-442 (1992)
	ES	MILLER et al, "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J Exp Med</u> 174:791-798 (1991)
	ET	MORI et al, "Mass Spectrometry of Purified Amyloid β Protein in Alzheimer's Disease," <u>J Biol Chem</u> 267(24):17082-17088 (1992)
	EU	MORRIS et al, "The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> 39:1159-1165 (1989)
	EV	MURPHY et al, "Development of a Monoclonal Antibody Specific for the COOH-Terminal of β -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am J Pathol</u> 144(5):1082-1088 (1994)
	EW	NEWCOMBE et al, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim Biophys Acta</u> 104:480-486 (1965)
	EX	PARDRIDGE et al, "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem Biophys Res Comm</u> 146:307-313 (1987)
	EY	PRIEELS et al, "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406t (1994)
	EZ	QUON et al, "Formation of β -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> 352:239-241 (1991)
	FA	ROGERS et al, "Complement activation by β -amyloid in Alzheimer Disease," <u>Proc Natl Acad Sci USA</u> , 89:1-5 (1992)
	FB	ROSSOR et al, "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Ann of NY Acad Sci</u> , 695:198-202 (1993)
EDO	FC	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976)


Examiner Signature

Date Considered

7/13/03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7

of 8

Complete if Known

Application Number	09/441,140
Filing Date	November 16, 1999
First Named Inventor	Beka SOLOMON
Group Art Unit	1042 <i>Kalff</i>
Examiner Name	S. <i>Solomon</i> NICHOLS

Attorney Docket Number SOLOMON=1R

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
<i>CGW</i>	FD	SAIDO et al, "Spatial Resolution of the Primary β -Amyloidogenic Process Induced in Postischemic Hippocampus," <i>J Biol Chem</i> 269(21):15253-15257 (1994)	
	FE	SAIDO et al, "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <i>J Biol Chem</i> 268(33):25239-25243 (1993)	
	FF	SAITO et al, "Immunological Analysis of Alzheimer's Disease Using Anti- β -protein Monoclonal Antibodies," <i>Sapporo Med J</i> 60:309-320 (1991)	
	FG	SELKOE DJ "Alzheimer's Disease: A Central Role for Amyloid," <i>J Neuropathol Exp Neurol</i> 53(5): 438-447 (1994)	
	FH	SELKOE DJ, "Physiological production of the β -amyloid protein and the mechanism of Alzheimer's disease," <i>Trends Neurosci</i> , 16(10):403-409 (1993)	
	FI	SELKOE DJ, "Alzheimer's disease. In the Beginning..." <i>Nature</i> 354(6353):432-433 (1991)	
	FJ	SELKOE DJ, "Amyloid Protein and Alzheimer's Disease," <i>Sci Am</i> 265(5):68-78 (1991)	
	FK	SELKOE DJ, "The Molecular pathology of Alzheimer's Disease," <i>Neuron</i> 6(4):487-498 (1991)	
	FL	SHIOSAKA S "Attempts to make models for Alzheimer's disease," <i>Neurosci Res</i> 13(4):237-255 (1992)	
	FM	TRIEB et al, "Is Alzheimer β amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <i>Immunobiology</i> , 191(2-3):114-115 Abstract C.37 (1994)	
<i>CGW</i>	FN	VAN GOOL et al, "Concentrations of amyloid- β protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <i>Neurosci Lett</i> 172:122-124 (1994)	
<i>CGW</i>	FO	VERBEEK et al, "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <i>Am J Pathol</i> 144(1):104-116 (1994)	

Examiner Signature

G. Meier

Date Considered

7/30/03


TECH CENTER 1600/2000

NOV 15 2002


RECEIVED

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	09/441,140
(use as many sheets as necessary)		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	<u>1642</u> <u>1647</u>
		Examiner Name	<u>S. Unger</u> <u>NICOLAS</u>
Sheet	8	of	8
		Attorney Docket Number	
		SOLOMON=1R	

Examiner Signature		Date Considered	7/30/03
--------------------	---	-----------------	---------


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449A/PTO-1 U.S. PATENT & TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642 1647
		Examiner Name	E. Bansen NICHOLS
Sheet	1	of	2
		Attorney Docket Number	
		SOLOMON=1R	

RECEIVED
MAR 06 2002
TECH CENTER 1600/2800

Examiner Signature		Date Considered	7/30/2003
-----------------------	---	--------------------	-----------


* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449 PTO U.S. PATENT & TRADEMARK OFFICE		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	09/441,140
		Filing Date	November 16, 1999
		First Named Inventor	Beka SOLOMON
		Group Art Unit	1642 1647
		Examiner Name	G. Bensee NICHOLS
		Attorney Docket Number	SOLOMON=1R
Sheet	2	of	2

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	7/30/03
--------------------	---	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.